OXFORD BIODYNAMICS LS-,01 Aktie

Oxford BioDynamics has entered into a partnership with the Dubai London Clinics & Hospitals Group (DLCH) to offer the prostate cancer test EpiSwitch PSE across DLCH’s clinic and hospital network in the United Arab Emirates. Patient blood samples will be collected at DLCH facilities and analyzed at Oxford BioDynamics’ laboratory in the UK; the clinical workflow has been validated by both partners. The agreement is the first commercial rollout of the test in the Gulf region; market launch, local market development and collaboration with payers are intended to gradually increase test volumes. » More on de.investing.com

Oxford BioDynamics raised about £9.15m by placing 9.15 billion new ordinary shares at £0.001 each; after fees roughly £8.4m is expected. The proceeds are intended to fund platform partnerships for EpiSwitch‑Orion, expansion of the prostate cancer test, development of a test for response to checkpoint inhibitors and completion of a colorectal cancer study. Without the financing, cash is expected to be exhausted in early September 2026; the transaction requires shareholder approval (AGM 26 Aug.) and AIM approval (27 Aug.). The company reported a significant capital loss under the Companies Act, and the board is considering alternative financing options, a sale or an orderly wind‑down if the proposal is rejected. » More on de.investing.com

Oxford BioDynamics has signed a sales agreement with MK Commercial Group to strengthen US distribution of EpiSwitch PSE. Initially seven field sales advisors will be deployed, with the number able to rise to as many as 35 to cover key population centers such as New Jersey, Washington D.C., Virginia, Georgia and Chicago. According to the company, the test for triage after elevated PSA levels has a positive predictive value of 93% and a specificity of 97% and is intended to reduce unnecessary biopsies. The sales representatives will operate under the commercial management of Oxford BioDynamics and will complement the existing sales infrastructure in Frederick, Maryland. » More on de.investing.com

Shareholders of Oxford BioDynamics have approved a capital increase to issue 2.33 billion new ordinary shares, raising around £7 million. The shares are expected to be issued in two tranches, likely on 10 and 11 November, leaving issued share capital at 4.29 billion ordinary shares. Several directors and executives participated in the placement, including Iain Ross and Alexandre Akoulitchev; Vulpes Investment Management (Stephen Diggle) increased its stake to 14.4%. Oak Securities acted as sole broker and Shore Capital as Nominated Adviser. » More on de.investing.com

Subject to shareholder approval on 7 November 2025, Oxford BioDynamics raised about £7 million by placing and subscribing for new ordinary shares. 2.3 billion shares were placed and 31.7 million directly subscribed, each at £0.003 per share (a 40% discount to the closing price on 21 October); the new shares would represent about 54.4% of the enlarged share capital. The proceeds will be used as working capital to support rising test sales and growth initiatives; the company reports strong growth in the EpiSwitch Prostate Screening Test and is expanding its partnership with Google Cloud while continuing development of EpiSwitch CiRT. » More on de.investing.com